ABVC BioPharma, Inc. reported on May 6, 2025, that it had received a notification from Nasdaq, indicating compliance with listing requirements after its stockholders' equity increased to $7,956,295 as of March 31, 2025, resolving a previous non-compliance issue. This follows an April 30, 2025, report where it had failed to meet Nasdaq’s criteria due to lower equity of $723,959.